TY - JOUR
T1 - Early-stage antibody kinetics after the third dose of BNT162b2 mRNA COVID-19 vaccination measured by a point-of-care fingertip whole blood testing
AU - Hagiya, Hideharu
AU - Nakano, Yasuhiro
AU - Furukawa, Masanori
AU - Sunada, Naruhiko
AU - Hasegawa, Toru
AU - Sakurada, Yasue
AU - Hasegawa, Kou
AU - Yamamoto, Koichiro
AU - Ogawa, Hiroko
AU - Obara, Takafumi
AU - Ageta, Kouhei
AU - Matsumoto, Naomi
AU - Matsuo, Rumi
AU - Kadowaki, Tomoka
AU - Higashikage, Akihito
AU - Hikita, Takao
AU - Yorifuji, Takashi
AU - Toyooka, Shinichi
AU - Maeda, Yoshinobu
AU - Yokokura, Yoshinori
AU - Otsuka, Fumio
AU - Nakayama, Masanori
N1 - Funding Information:
This study was supported by donations to the Okayama University Academic Capital Foundation (support for research related to COVID-19) and Grants-in-Aid for Scientific Research Fund for the Promotion of Joint International Research (Fostering Joint International Research (B). The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; or decision to submit the manuscript for publication.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Amid the Coronavirus Disease 2019 pandemic, we aimed to demonstrate the accuracy of the fingertip whole blood sampling test (FWT) in measuring the antibody titer and uncovering its dynamics shortly after booster vaccination. Mokobio SARS-CoV-2 IgM & IgG Quantum Dot immunoassay (Mokobio Biotechnology R&D Center Inc., MD, USA) was used as a point-of-care FWT in 226 health care workers (HCWs) who had received two doses of the BNT162b2 mRNA vaccine (Pfizer-BioNTech) at least 8 months prior. Each participant tested their antibody titers before and after the third-dose booster up to 14-days. The effect of the booster was observed as early as the fourth day after vaccination, which exceeded the detection limit (> 30,000 U/mL) by 2.3% on the fifth day, 12.2% on the sixth day, and 22.5% after the seventh day. Significant positive correlations were observed between the pre- and post-vaccination (the seventh and eighth days) antibody titers (correlation coefficient, 0.405; p < 0.001). FWT is useful for examining antibody titers as a point-of-care test. Rapid response of antibody titer started as early as the fourth day post-vaccination, while the presence of weak responders to BNT162b2 vaccine was indicated.
AB - Amid the Coronavirus Disease 2019 pandemic, we aimed to demonstrate the accuracy of the fingertip whole blood sampling test (FWT) in measuring the antibody titer and uncovering its dynamics shortly after booster vaccination. Mokobio SARS-CoV-2 IgM & IgG Quantum Dot immunoassay (Mokobio Biotechnology R&D Center Inc., MD, USA) was used as a point-of-care FWT in 226 health care workers (HCWs) who had received two doses of the BNT162b2 mRNA vaccine (Pfizer-BioNTech) at least 8 months prior. Each participant tested their antibody titers before and after the third-dose booster up to 14-days. The effect of the booster was observed as early as the fourth day after vaccination, which exceeded the detection limit (> 30,000 U/mL) by 2.3% on the fifth day, 12.2% on the sixth day, and 22.5% after the seventh day. Significant positive correlations were observed between the pre- and post-vaccination (the seventh and eighth days) antibody titers (correlation coefficient, 0.405; p < 0.001). FWT is useful for examining antibody titers as a point-of-care test. Rapid response of antibody titer started as early as the fourth day post-vaccination, while the presence of weak responders to BNT162b2 vaccine was indicated.
UR - http://www.scopus.com/inward/record.url?scp=85143090878&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143090878&partnerID=8YFLogxK
U2 - 10.1038/s41598-022-24464-3
DO - 10.1038/s41598-022-24464-3
M3 - Article
C2 - 36450786
AN - SCOPUS:85143090878
SN - 2045-2322
VL - 12
JO - Scientific reports
JF - Scientific reports
IS - 1
M1 - 20628
ER -
